Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
Adverse event
Cladribine
Disease-modifying treatment
Influenza A virus
Lymphopenia
Multiple Sclerosis
Journal
eNeurologicalSci
ISSN: 2405-6502
Titre abrégé: eNeurologicalSci
Pays: Netherlands
ID NLM: 101667077
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
02
06
2020
revised:
07
09
2020
accepted:
30
09
2020
entrez:
9
11
2020
pubmed:
10
11
2020
medline:
10
11
2020
Statut:
epublish
Résumé
To describe a fatal case of influenza A pneumonia in a patient with severe lymphopenia after receiving subcutaneous cladribine to treat her multiple sclerosis (MS). Case report. A 53-year-old woman developed fatal influenza pneumonia associated with grade 4 lymphopenia two months after receiving a total dose of 60mg subcutaneous cladribine. Despite treatment with oseltamivir, her condition deteriorated and the patient passed away after developing respiratory failure. Cladribine-related lymphopenia is usually mild to moderate, however severe lymphopenia may occur. People with MS, especially those who are immunosuppressed, should be offered the inactivated influenza vaccine annually.
Identifiants
pubmed: 33163633
doi: 10.1016/j.ensci.2020.100279
pii: S2405-6502(20)30058-7
pmc: PMC7599429
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100279Informations de copyright
© 2020 Published by Elsevier B.V.
Déclaration de conflit d'intérêts
MM-C has received presentation fees or grants from Sanofi-Genzyme and UCB Pharma. DB has received consultancy or presentation fees from Canbex Therapeutics, Japan Tobacco, Merck Roche and Sanofi Genzyme. KS has received presentation fees, meeting support or scientific advisory fees from Biogen, Lipomed, Merck Serono, Novartis, Roche and Teva. GG has received consultancy, presentation fees or grants from AbbVie Biotherapeutics, Bayer Healthcare, Biogen, Canbex, Celgene, Ironwood, Japan Tobacco, Novartis, Roche, Sanofi-Genzyme, Synthon, Takeda, Teva and Vertex. No other disclosures were reported.
Références
J Infect Public Health. 2019 Nov - Dec;12(6):878-883
pubmed: 31202719
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
Lancet Neurol. 2014 Mar;13(3):257-67
pubmed: 24502830
Infect Dis (Lond). 2019 Jul;51(7):543-546
pubmed: 31012776
N Engl J Med. 2010 Feb 4;362(5):416-26
pubmed: 20089960
Mult Scler. 2018 Oct;24(12):1594-1604
pubmed: 28870107
Mult Scler Relat Disord. 2019 Jan;27:247-253
pubmed: 30419510
J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1266-1271
pubmed: 29991490
Neurology. 2020 Oct 6;95(14):e1999-e2008
pubmed: 32727835
Mult Scler. 2009 Jun;15(6):767-70
pubmed: 19482866
Mult Scler. 2011 May;17(5):578-93
pubmed: 21228029